Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer-Reference-Cited by-同舟云学术

Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer

Published:2023-06 Issue:06 Volume:83 Page:664-672
ISSN:0016-5751
Container-title:Geburtshilfe und Frauenheilkunde
language:de
Short-container-title:Geburtshilfe Frauenheilkd

Author:

Lux Michael P.¹,Hartkopf Andreas D.²,Fehm Tanja N.³,Welslau Manfred⁴,Müller Volkmar⁵,Schütz Florian⁶,Fasching Peter A.⁷,Janni Wolfgang²,Witzel Isabell⁸,Thomssen Christoph⁹,Beierlein Milena⁷,Belleville Erik¹⁰,Untch Michael¹¹,Thill Marc¹²,Tesch Hans¹³,Ditsch Nina¹⁴,Aktas Bahriye¹⁵,Banys-Paluchowski Maggie¹⁶,Kolberg-Liedtke Cornelia¹⁷,Wöckel Achim¹⁸,Kolberg Hans-Christian¹⁹,Harbeck Nadia²⁰,Bartsch Rupert²¹,Schneeweiss Andreas²²,Ettl Johannes²³,Würstlein Rachel²⁰,Krug David²⁴,Taran Florin-Andrei²⁵,Lüftner Diana²⁶,Stickeler Elmar²⁷

Affiliation:

1. Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany

2. Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany

3. Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany

4. Onkologie Aschaffenburg, Aschaffenburg, Germany

5. Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany

6. Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany

7. Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany

8. Klinik für Gynäkologie, Universitätsspital Zürich, Zürich, Switzerland

9. Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany

10. ClinSol GmbH & Co KG, Würzburg, Germany

11. Clinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany

12. Department of Gynecology and Gynecological Oncology, Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany

13. Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany

14. Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany

15. Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany

16. Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

17. Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany

18. Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany

19. Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany

20. Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, München, Germany

21. Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria

22. National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany

23. Klinik für Frauenheilkunde und Gynäkologie, Klinikum Kempten, Klinikverbund Allgäu, Kempten, Germany

24. Klinik für Strahlentherapie, Universitätsklinkum Schleswig-Holstein, Campus Kiel, Kiel, Germany

25. Department of Gynecology and Obstetrics, University Hospital Freiburg, Freiburg, Germany

26. Medical University of Brandenburg Theodor-Fontane, Immanuel Hospital Märkische Schweiz, Buckow, Germany

27. Department of Obstetrics and Gynecology, Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf), University Hospital of RWTH Aachen, Aachen, Germany

Abstract

AbstractIn recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the Destiny-Breast03 study, the first analysis of the CAPItello-291 study, the comparison of CDK4/6 inhibitor treatment with chemotherapy in the first line of therapy (RIGHT Choice study), the first analysis of the Destiny-Breast02 study in the treatment setting after T-DM1 treatment, and the first analysis of the Serena-2 study.Most of these studies have the potential to significantly change the therapeutic landscape for patients with advanced breast carcinoma and show that the continued rapid development of new therapies is always producing new results.

Publisher

Georg Thieme Verlag KG

Subject

Maternity and Midwifery,Obstetrics and Gynecology

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-2074-0125.pdf

Reference29 articles.

1. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021;N Ditsch;Breast Care (Basel),2021

2. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5);F Cardoso;Ann Oncol,2020

3. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer – Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany;A Schneeweiss;Breast,2020

4. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry;AD Hartkopf;Breast,2018

5. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium;DJ Lobbezoo;Ann Oncol,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry;Geburtshilfe und Frauenheilkunde;2024-05

2. Spiritual care needs and their attributes among Chinese inpatients with advanced breast cancer based on the Kano model: a descriptive cross-sectional study;BMC Palliative Care;2024-02-22

3. Molekulargenetische Testung bei Brust- und Eierstockkrebs und die Konsequenzen;best practice onkologie;2023-11